Magdi Elsallab

Harvard University — United States

Medicine · Health Sciences

10h-index850citations26works16.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(17), Biomedical Ethics and Regulation(9), Biosimilars and Bioanalytical Methods(6), Viral Infectious Diseases and Gene Expression in Insects(5), 3D Printing in Biomedical Research(3)

Publications26 total

Triple base-edited dual targeting CD70/33 CAR T cells to avoid cytokine-mediated resistance in Acute Myeloid Leukemia
Blood·2025
Postmarketing safety profile of chimeric antigen receptor (CAR) T cell therapies in diffuse large B-cell lymphoma (DLBCL): Analysis of real-world (RW) AE reporting from the FDA Adverse Event Reporting System (FAERS).
Journal of Clinical Oncology·2025
Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene Therapies
JAMA Internal Medicine·2025· 2 citedOpen Access
Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data
Transplantation and Cellular Therapy·2024· 23 cited
Mapping the Clinical Development Trajectory of Cell and Gene Therapy Products
Clinical Pharmacology & Therapeutics·2024· 3 citedOpen Access
Charting the course for CAR T-cell manufacturing
Blood Advances·2024· 1 citedOpen Access
Decentralizing gene and cell therapy manufacturing: changing tides or uphill battle
Cell and Gene Therapy Insights·2024
ACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies
Transplantation and Cellular Therapy·2024· 5 citedOpen Access
National Survey of FACT-Accredited Cell Processing Facilities: Assessing Preparedness for Local Manufacturing of Immune Effector Cells
Transplantation and Cellular Therapy·2024· 5 cited
Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System
Blood·2024· 124 citedOpen Access
Expanding access to CAR T cell therapies through local manufacturing
Nature Biotechnology·2023· 51 cited
CAR NK-92 cell–mediated depletion of residual TCR+ cells for ultrapure allogeneic TCR-deleted CAR T-cell products
Blood Advances·2023· 11 citedOpen Access
Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
2023Open Access
Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
2023Open Access
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
2023Open Access
Supplementary Data from Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
2023Open Access
Vitamin D Status in Egypt and its Seasonal Variation During Infancy and Preschool Children
The Medical Journal of Cairo University/˜The œMedical Journal of Cairo University·2023
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
Cancer Gene Therapy·2023· 48 citedOpen Access
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Blood Cancer Discovery·2021· 263 citedOpen Access
Detection of SARS‐CoV‐2‐specific memory B cells to delineate long‐term COVID‐19 immunity
Allergy·2021· 10 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Mohamed Abou‐El‐Enein(14), Marcela V. Maus(7), Steven A. Feldman(5), Andrew D. Fesnak(5), Helen E. Heslop(5), Peter Marks(5), Brian G. Till(5), Barbara Savoldo(5), Moataz Ellithi(4), Gerhard Bauer(4), Matthew A. Lunning(3), Enrico Fritsche(3), Florence T. Bourgeois(3), Gerhard Bauer(2), Christopher R. D’Angelo(2), Jihyun Ma(2), Matthew J. Frigault(2), Armin Kurtz(2), Constantin J. Thieme(2), Moritz Anft(2)